Women with multiple primary breast cancers diagnosed within a five year period, 1994-1998

被引:9
|
作者
Howe, HL
Weinstein, R
Alvi, R
Kohler, B
Ellison, JH
机构
[1] NAACCR, Springfield, IL 62704 USA
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Saskatchewan Canc Registry, Regina, SK, Canada
[4] New Jersey State Canc Registry, Trenton, NJ USA
关键词
breast cancer; epidemiology; multiple primary tumors; neoplasm; surveillance;
D O I
10.1007/s10549-004-4258-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction. Women diagnosed with a primary breast cancer are at higher risk for a second primary. Few studies have focused on a comparison of women with single breast primary cancers and women with multiple primary breast cancers. The 1994-1998 NAACCR dataset aggregated from high quality registries representing more than one-third of the US population provides a unique opportunity to examine the incidence of multiple primary breast cancers in a large population. Materials and methods. Using this multi-registry dataset, we describe the incidence pattern of malignant synchronous (within 2 months) and short-term metachronous (from 3 to 60 months) multiple primaries and single primary breast cancers by demographic and tumor characteristics. Results. Synchronous multiple primary tumors were more similar in age, stage, and tumor grade to single breast tumors than they were to short-term metachronous tumors. The short-term metachronous tumors did not resemble either the synchronous tumors or the single primaries. Discussion. These findings may indicate that while synchronous multiple primaries may have treatment implications different from single primaries, their etiology may be similar to single breast primaries. Further, they may actually be multi-centric single primaries. The two-month interval between multiple primaries is arbitrary and may not distinguish between the synchronous tumors and those occurring within 12 months of the index tumor. The rules for defining and counting breast primaries have implications for interpretation of incidence rates and temporal trends. These data also suggest the need for standard definitions for multiple primary breast tumors among clinicians, pathologists, and surveillance epidemiologists.
引用
收藏
页码:223 / 232
页数:10
相关论文
共 24 条
  • [21] Results from London Regional Clinical Genetics services over a 5-year period on germline TP53 testing in women diagnosed with breast cancer at <30 years
    Garrett, Alice
    Talukdar, Sabrina
    Izatt, Louise
    Brady, Angela F.
    Whyte, Sinead
    Josephs, Katherine S.
    Shanmugasundaram, Monisha
    Guillemot, Li Shan
    Vakili, Dara
    Ey, Shevaun
    Ahmed, Munaza
    [J]. JOURNAL OF MEDICAL GENETICS, 2022, 59 (06) : 554 - 558
  • [22] FIVE-YEAR HEALTHCARE RESOURCE CONSUMPTION AND DIRECT COSTS OF WOMEN WITH A NEW DIAGNOSIS OF HR+/HER2-BREAST CANCER PRIMARY OR ADVANCED: ANALYSIS OF A LARGE ITALIAN ADMINISTRATIVE DATABASE
    Dell'Anno, I
    Ronconi, G.
    Dondi, L.
    Dondi, L.
    Calabria, S.
    Piccinni, C.
    Esposito, I
    Addesi, A.
    Pedrini, A.
    Maggioni, A. P.
    Martini, N.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S254 - S254
  • [23] Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group Study
    Mansi, Janine L.
    Yellowlees, Ann
    Lipscombe, Julian
    Earl, Helena M.
    Cameron, David A.
    Coleman, Robert E.
    Perren, Timothy
    Gallagher, Christopher J.
    Quigley, Mary
    Crown, John
    Jones, Alison L.
    Highley, Martin
    Leonard, Robert C. F.
    Evans, T. R. Jeffry
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (03) : 787 - 794
  • [24] Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group Study
    Janine L. Mansi
    Ann Yellowlees
    Julian Lipscombe
    Helena M. Earl
    David A. Cameron
    Robert E. Coleman
    Timothy Perren
    Christopher J. Gallagher
    Mary Quigley
    John Crown
    Alison L. Jones
    Martin Highley
    Robert C. F. Leonard
    T. R. Jeffry Evans
    [J]. Breast Cancer Research and Treatment, 2010, 122 : 787 - 794